CPK850
Sponsors
Novartis Pharma AG, Novartis Pharmaceuticals
Conditions
Retinitis PigmentosaRetinitis pigmentosa caused by biallelic mutations in the RLBP1 gene
Phase 1
A First-in-human, Proof of Concept Study of CPK850 in Patients With RLBP1 Retinitis Pigmentosa
CompletedNCT03374657
Start: 2018-08-22End: 2026-05-12Updated: 2026-06-11
An open-label first-in-human single ascending dose study to explore the safety, tolerability and efficacy of subretinal administration of CPK850 gene therapy in patients with retinitis pigmentosa caused by mutations in the RLBP1 gene
Active, not recruitingCTIS2023-508688-54-00
Start: 2018-08-22Target: 21Updated: 2025-02-18